About DMC Biotechnologies
DMC Biotechnologies is a Chemicals & Materials company based in Boulder (United States) founded in 2014 by Mike Lynch and Matt Lipscomb. Bio-based chemicals including amino acids and sweeteners are manufactured. It operates on a Product-as-a-Service and Direct-to-Consumer (D2C) model. DMC Biotechnologies has raised $73.04 million across 15 funding rounds from investors including Michelin, SCG and Toyobo Global. Its chief executive, as recorded, is Jim Flatt. DMC Biotechnologies offers products and services including D-Chiro-Inositol, Myo-Inositol, and Bio-Based Chemicals. Its focus areas include Biotechnology, Industrial Biotechnology and Bio-Based Chemicals. Its legal entity is DMC Biotechnologies, Inc. Its competitors include LanzaTech, Manus Bio and P2 Science; 3 of its 3 listed competitors have raised funding.
Company details
DMC Biotechnologies is focused on transforming the specialty chemical industry by producing sustainable, bio-based ingredients using precision fermentation. Operations span dietary supplements, nutraceuticals, cosmetic actives, and bio-based chemicals for various markets. The proprietary Dynamic Metabolic Control technology is utilized to ensure cost-effective, reliable, and scalable production. Emphasis is placed on environmental responsibility, safety, and health standards. Collaborations are fostered to accelerate product development from concept to commercial scale, while supply chain security is enhanced through local production using agricultural feedstocks.
- Headquarters Boulder, United States
- Founders Mike Lynch, Matt Lipscomb
- SectorsChemicals & Materials
- Phone•••• ••••
- Website dmcbio.com
- Social LinkedIn X YouTube
- Legal Name Dmc Biotechnologies, Inc.
- Total Equity Funding$73.04M (USD)
in 15 rounds
- Latest Funding Round$18M (USD), Series C
Oct 2026
- InvestorsMichelin
& 17 more
Products & Services of DMC Biotechnologies
DMC Biotechnologies offers a comprehensive portfolio of products and services, including D-Chiro-Inositol, Myo-Inositol, and Bio-Based Chemicals.
A sustainable nutraceutical ingredient for modern formulation needs.
A cleaner, fermented ingredient for health-focused brand formulations.
Sustainable chemicals produced for diverse industrial market applications.
Apps and channels of DMC Biotechnologies
its YouTube channel DMCBiotech has 25 subscribers and 21 videos.
Videos from DMC Biotechnologies
The most watched videos on DMC Biotechnologies's YouTube channel, DMCBiotech (25 subscribers). Click a video to play it here.
More on DMCBiotech.
Funding Insights of DMC Biotechnologies
DMC Biotechnologies has successfully raised a total of $73.04M across 15 strategic funding rounds. The most recent funding activity was a Series C round of $18 million completed in October 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $73.04M
- Total Rounds 15
- Last Round Series C — $18M
- First Round $241,250
(Jan 2016)
- Investors Count 18
Latest 10 of 15 funding rounds of DMC Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2026 | $18M | Series C | – | Sofinnova Partners | |
| Dec 2025 | $1.41M | Series C | – | – | – |
| Oct 2025 | $904,500 | Series C | – | – | – |
| Apr 2025 | $4.79M | Series C | – | – | – |
| Aug 2022 | $66,720 | Series B | – | – | – |
| Feb 2022 | Series B | – | – | ||
| Dec 2021 | $34M | Series B | – | Quest for Growth, Cibus Fund | |
| Jan 2021 | $22,446 | Series A | – | – | – |
| Jun 2019 | $11.3M | Series A | – | Sofinnova Partners | |
| Mar 2019 | $2.54M | Seed | – | Capricorn Partners | – |
18 investors in total: 14 institutional and 4 angel.
Investors in DMC Biotechnologies
DMC Biotechnologies has secured backing from 18 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Michelin, SCG and Toyobo Global.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth-stage life sciences and tech companies in Europe are funded. | 1998 | questforgrowth.com | Leuven, Belgium | |
Investment funds focused on sustainable food and agriculture are managed. | cibusfund.com | London, United Kingdom | ||
Investments are directed by Capricorn Partners into European tech ventures. | 1993 | capricorn.be | Leuven, Belgium | |
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Climate solutions are advanced via venture capital and startup acceleration. | breakthroughenergy.org | Kirkland, United States | ||
Venture capital is offered by Boulder Ventures for innovative companies. | boulderventures.com | Boulder, United States | ||
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
| firstbight.com | ||||
Functional polymers, industrial materials, and healthcare products are provided. | 1882 | toyobo-global.com | New York, United States |
Investor details for DMC Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DMC Biotechnologies
15 people are tracked at DMC Biotechnologies (8 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Mike Lynch | Co-Founder | Leadership |
Matt Lipscomb | Co-Founder | Leadership |
Jim Flatt | CEO | Leadership |
Joško B. | Director Board Of Directors | Leadership |
Marcel Lubben | Vice President Strategic Alliances | Leadership |
Laurent Kieken | Sr Director of Business Development | Leadership |
Rusty Pittman | Vice President Of Business Development | Leadership |
Trevor Rosensohn | Director, Downstream Processing | Leadership |
Cathy St Louis | Facility and Lab Manager | Team |
Jacob Wolf | Engineer 2 - Downstream Processing | Team |
Alexis Venegas | DSP Engineer 1 | Team |
Moses Onyeabor | Metabolic Engineer | Team |
Taylor Lundy | Scientist Ii, Metabolic Engineering | Team |
Kyle Lang | Business Development Manager | Team |
Brad Edgerton | Project Manager | Team |
Complete people profiles for DMC Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DMC Biotechnologies
3 dated milestones of DMC Biotechnologies across 12 years, from founding to its latest funding, stage changes and deals.
- Founded DMC Biotechnologies is founded.
- Funding First funding round of $241K.
- Funding Latest funding round, Series C, of $18.0M.
Competitors of DMC Biotechnologies
DMC Biotechnologies has 3 listed competitors in our database, 3 of them funded. They include LanzaTech, Manus Bio and P2 Science.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lanzatech.com | 2005 | Skokie, United States | $869.3M | 367 | Waste carbon is treated via a bio-processing platform. | |
| manusbio.com | 2011 | Cambridge, United States | $115.93M | Phytochemicals are developed using microbial fermentation processes. | ||
| p2science.com | 2011 | Woodbridge, United States | $39.16M | 1 | Diversified green chemicals are manufactured from bio-renewable resources. |
Detailed competitors of DMC Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DMC Biotechnologies
The website of DMC Biotechnologies (dmcbio.com) receives about 3.1K visits a month.
- Monthly visits3.1K
Websites whose visitors overlap most with DMC Biotechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| altisbiosystems.com | 100% | 16.6K | #1,779,798 | View details | |
| catawbaresearch.com | 100% | 3.5K | #5,071,999 | View details | |
| saperebio.com | 100% | View details | |||
| lifeeditinc.com | 97% | View details | |||
| xilis.com | 91% | 2.5K | #6,836,474 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for DMC Biotechnologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Chemicals Tech
3 companies that operate in the same segment as DMC Biotechnologies (Chemicals Tech) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Microbe-based plant protection products and yield optimization services are provided. | 2013 | Boston, Massachusetts, United States | USD 1.4 B | 1,316 | ||
Conductive nanocoatings are delivered via atomic layer deposition technology. | 2013 | Boulder, Colorado, United States | USD 202.75 M | |||
Sustainable bio-based chemicals are manufactured using a proprietary platform. | 2016 | Houston, Texas, United States | USD 656.05 M | 133 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dmc Biotechnologies
Complete news archive for DMC Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DMC Biotechnologies
DMC Biotechnologies was founded in 2014 and raised its 1st funding round 2 years after it was founded.
DMC Biotechnologies is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Jim Flatt is the CEO of DMC Biotechnologies, as recorded in our data.
DMC Biotechnologies is a funded company, having raised a total of $73.04M across 15 funding rounds to date. The company's 1st funding round was a Seed of $2.54M, raised on Jan 2016.
DMC Biotechnologies is focused on transforming the specialty chemical industry by producing sustainable, bio-based ingredients using precision fermentation. Operations span dietary supplements, nutraceuticals, cosmetic actives, and bio-based chemicals for various markets. The proprietary Dynamic Metabolic Control technology is utilized to ensure cost-effective, reliable, and scalable production. Emphasis is placed on environmental responsibility, safety, and health standards. Collaborations are fostered to accelerate product development from concept to commercial scale, while supply chain security is enhanced through local production using agricultural feedstocks.
DMC Biotechnologies's top competitors include Manus Bio, LanzaTech and P2 Science.
DMC Biotechnologies offers D-Chiro-Inositol, Myo-Inositol, and Bio-Based Chemicals.
DMC Biotechnologies has 18 investors. Key investors include Michelin, SCG, Toyobo Global, Solvay, and Capricorn Partners.
DMC Biotechnologies operates through Dmc Biotechnologies, Inc..